SG10202006338UA - Syntac polypeptides and uses thereof - Google Patents
Syntac polypeptides and uses thereofInfo
- Publication number
- SG10202006338UA SG10202006338UA SG10202006338UA SG10202006338UA SG10202006338UA SG 10202006338U A SG10202006338U A SG 10202006338UA SG 10202006338U A SG10202006338U A SG 10202006338UA SG 10202006338U A SG10202006338U A SG 10202006338UA SG 10202006338U A SG10202006338U A SG 10202006338UA
- Authority
- SG
- Singapore
- Prior art keywords
- syntac polypeptides
- syntac
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013715P | 2014-06-18 | 2014-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202006338UA true SG10202006338UA (en) | 2020-08-28 |
Family
ID=54936224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609876TA SG11201609876TA (en) | 2014-06-18 | 2015-06-15 | Syntac polypeptides and uses thereof |
| SG10202006338UA SG10202006338UA (en) | 2014-06-18 | 2015-06-15 | Syntac polypeptides and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609876TA SG11201609876TA (en) | 2014-06-18 | 2015-06-15 | Syntac polypeptides and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20170058015A1 (en) |
| EP (3) | EP3157552B1 (en) |
| JP (4) | JP6652932B2 (en) |
| KR (1) | KR102252119B1 (en) |
| CN (3) | CN113248623A (en) |
| AU (3) | AU2015277460B2 (en) |
| BR (1) | BR112016027897A2 (en) |
| CA (1) | CA2947489A1 (en) |
| DK (2) | DK3480213T3 (en) |
| ES (2) | ES2770330T3 (en) |
| HU (2) | HUE047255T2 (en) |
| IL (3) | IL248979B (en) |
| PL (2) | PL3480213T3 (en) |
| PT (2) | PT3157552T (en) |
| SG (2) | SG11201609876TA (en) |
| TW (3) | TWI696633B (en) |
| WO (1) | WO2015195531A2 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201504558TA (en) | 2012-12-11 | 2015-07-30 | Einstein Coll Med | Methods for high throughput receptor:ligand identification |
| US20190062400A1 (en) * | 2016-03-02 | 2019-02-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2017151940A2 (en) * | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN109689096A (en) * | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | Variant PD-L1 polypeptide, T cell modulability multimeric polypeptide and its application method |
| KR20190019068A (en) * | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-cell modulated multimeric polypeptides and methods for their use |
| WO2018027252A1 (en) * | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| IL266696B2 (en) * | 2016-12-22 | 2023-04-01 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR102619015B1 (en) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | How to Regulate Your Immune Response |
| WO2018187190A1 (en) * | 2017-04-06 | 2018-10-11 | Albert Einstein College Of Medicine, Inc. | Precision activation of hiv-specific ctls to eliminate reactived latent t cells |
| KR20200016954A (en) * | 2017-06-12 | 2020-02-17 | 시나이 헬스 시스템 | Allogeneic graft resistance without systemic immunosuppression |
| CN107266581B (en) * | 2017-06-13 | 2021-07-09 | 四川大学 | Preparation method and application of Tibetan pig IL-12 recombinant plasmid enhanced PCV2 vaccine immunologic adjuvant |
| EP3678677A4 (en) * | 2017-09-07 | 2021-06-16 | Cue Biopharma, Inc. | Antigen-presenting polypeptides and methods of use thereof |
| CA3070484A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| TW201925235A (en) * | 2017-09-07 | 2019-07-01 | 美商信號生物製藥公司 | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| KR20200064085A (en) * | 2017-09-07 | 2020-06-05 | 큐 바이오파마, 인크. | T-cell regulatory multimeric polypeptide having a conjugation site and a method of using the same |
| EP3512874A2 (en) * | 2017-11-30 | 2019-07-24 | Grifols Diagnostic Solutions Inc. | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1 |
| CN111886241A (en) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | Multimeric T cell modulating polypeptides and methods of use thereof |
| RU2020131383A (en) | 2018-03-24 | 2022-04-26 | Ридженерон Фармасьютикалз, Инк. | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR THE PRODUCTION OF THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR THEIR PRODUCTION AND APPLICATIONS |
| US20220047710A1 (en) * | 2018-09-12 | 2022-02-17 | Washington University | Single chain constructs |
| AU2019401183A1 (en) * | 2018-12-19 | 2021-08-12 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| TW202039542A (en) * | 2018-12-19 | 2020-11-01 | 美商庫爾生物製藥有限公司 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2020132368A1 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| EP3935079A4 (en) * | 2019-03-06 | 2023-03-22 | Cue Biopharma, Inc. | T-cell modulatory antigen-presenting polypeptides and methods of use thereof |
| CN114126635A (en) * | 2019-05-29 | 2022-03-01 | Cue生物制药股份有限公司 | Multimeric T cell modulating polypeptides and methods of use thereof |
| WO2020257191A1 (en) * | 2019-06-19 | 2020-12-24 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| MX2022003367A (en) * | 2019-09-20 | 2022-04-11 | Cue Biopharma Inc | T-cell modulatory polypeptides and methods of use thereof. |
| CA3146917A1 (en) * | 2019-10-23 | 2021-04-29 | Anish SURI | T-cell modulatory chimeric molecules and methods of use thereof |
| AU2020407233A1 (en) | 2019-12-20 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Novel IL2 agonists and methods of use thereof |
| WO2021168122A1 (en) * | 2020-02-18 | 2021-08-26 | Institute For Systems Biology | Single chain trimer mhc class ii nucleic acids and proteins and methods of use |
| WO2021168388A1 (en) * | 2020-02-21 | 2021-08-26 | 3T Biosciences, Inc. | Yeast display libraries, associated compositions, and associated methods of use |
| WO2021178975A1 (en) * | 2020-03-06 | 2021-09-10 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
| CN116096405A (en) | 2020-05-12 | 2023-05-09 | Cue生物制药股份有限公司 | Multimeric T cell modulating polypeptides and methods of use thereof |
| EP4149953A1 (en) * | 2020-05-12 | 2023-03-22 | Lg Chem, Ltd. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN112779224A (en) * | 2021-01-27 | 2021-05-11 | 河南省华隆生物技术有限公司 | NK trophoblast cell expressing cytokine composition and preparation method and application thereof |
| CN112852744A (en) * | 2021-01-27 | 2021-05-28 | 河南省华隆生物技术有限公司 | NK trophoblast cell and preparation method and application thereof |
| CN112725284A (en) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | NK trophoblast cell and application thereof |
| CN112725273A (en) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | NK cell and preparation method and application thereof |
| WO2022216974A1 (en) * | 2021-04-07 | 2022-10-13 | Repertoire Immune Medicines, Inc. | Peptide-mhc-immunoglobulin multimers and methods of use thereof |
| WO2022236102A1 (en) * | 2021-05-07 | 2022-11-10 | Institute For Systems Biology | Single chain trimer mhc class i nucleic acids and proteins and methods of use |
| WO2023022965A2 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| WO2023126544A1 (en) * | 2022-01-03 | 2023-07-06 | Aarhus Universitet | Proteinaceous compound for generating specific cytotoxic t-cell effect |
| WO2023205728A2 (en) * | 2022-04-21 | 2023-10-26 | Institute For Systems Biology | Soluble single-chain dimers from cleavable single chain trimers |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| JP3534749B2 (en) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | Adenovirus-mediated gene transfer into the gastrointestinal tract |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
| JPH08503855A (en) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | Gene therapy for cystic fibrosis |
| JP3532566B2 (en) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | Adenovirus vectors for gene therapy |
| RU2162342C2 (en) | 1993-10-25 | 2001-01-27 | Кэнджи Инк. | Recombinant adenoviral vector and methods of its using |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| US20050003431A1 (en) * | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| AU2002240818C1 (en) * | 2001-03-14 | 2008-11-06 | Agilent Technologies, Inc. | MHC molecule constructs and their uses for diagnosis and therapy |
| DE102004014983A1 (en) * | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Recombinant polypeptides of the members of the TNF ligand family and their use |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP2863222A1 (en) | 2006-03-06 | 2015-04-22 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| US8518697B2 (en) * | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| EP2361930A3 (en) * | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| NZ628987A (en) | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| MX354660B (en) | 2012-11-30 | 2018-03-14 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins. |
-
2015
- 2015-06-15 PL PL18212801T patent/PL3480213T3/en unknown
- 2015-06-15 DK DK18212801.7T patent/DK3480213T3/en active
- 2015-06-15 CN CN202110210453.7A patent/CN113248623A/en active Pending
- 2015-06-15 AU AU2015277460A patent/AU2015277460B2/en active Active
- 2015-06-15 PL PL15809277T patent/PL3157552T3/en unknown
- 2015-06-15 US US15/306,678 patent/US20170058015A1/en not_active Abandoned
- 2015-06-15 SG SG11201609876TA patent/SG11201609876TA/en unknown
- 2015-06-15 HU HUE15809277A patent/HUE047255T2/en unknown
- 2015-06-15 ES ES18212801T patent/ES2770330T3/en active Active
- 2015-06-15 PT PT158092775T patent/PT3157552T/en unknown
- 2015-06-15 BR BR112016027897A patent/BR112016027897A2/en active Search and Examination
- 2015-06-15 KR KR1020167034341A patent/KR102252119B1/en active IP Right Grant
- 2015-06-15 CN CN202110210461.1A patent/CN113248624A/en active Pending
- 2015-06-15 ES ES15809277T patent/ES2767259T3/en active Active
- 2015-06-15 PT PT182128017T patent/PT3480213T/en unknown
- 2015-06-15 SG SG10202006338UA patent/SG10202006338UA/en unknown
- 2015-06-15 CN CN201580027510.0A patent/CN106456733B/en active Active
- 2015-06-15 CA CA2947489A patent/CA2947489A1/en active Pending
- 2015-06-15 EP EP15809277.5A patent/EP3157552B1/en active Active
- 2015-06-15 HU HUE18212801A patent/HUE048076T2/en unknown
- 2015-06-15 EP EP18212801.7A patent/EP3480213B1/en active Active
- 2015-06-15 DK DK15809277.5T patent/DK3157552T3/en active
- 2015-06-15 JP JP2016565693A patent/JP6652932B2/en active Active
- 2015-06-15 EP EP18212805.8A patent/EP3483179B1/en active Active
- 2015-06-15 WO PCT/US2015/035777 patent/WO2015195531A2/en active Application Filing
- 2015-06-17 TW TW104119612A patent/TWI696633B/en active
- 2015-06-17 TW TW108133859A patent/TWI722576B/en active
- 2015-06-17 TW TW110108178A patent/TWI795740B/en active
-
2016
- 2016-11-15 IL IL248979A patent/IL248979B/en active IP Right Grant
-
2018
- 2018-06-06 US US16/001,153 patent/US20180282392A1/en not_active Abandoned
-
2019
- 2019-05-12 IL IL266570A patent/IL266570B/en active IP Right Grant
- 2019-05-16 AU AU2019203442A patent/AU2019203442B2/en active Active
- 2019-10-23 JP JP2019192453A patent/JP6652680B2/en active Active
-
2020
- 2020-01-13 US US16/740,752 patent/US20200377569A1/en not_active Abandoned
- 2020-01-24 JP JP2020009921A patent/JP6995151B2/en active Active
- 2020-06-11 IL IL275307A patent/IL275307B/en unknown
- 2020-08-25 US US17/001,847 patent/US20210238254A1/en active Pending
- 2020-09-09 US US17/015,282 patent/US20210047384A1/en active Pending
-
2021
- 2021-07-01 AU AU2021204594A patent/AU2021204594A1/en active Pending
- 2021-12-14 JP JP2021202405A patent/JP7331075B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275307B (en) | Syntac polypeptides and uses thereof | |
| IL281273A (en) | Modified fgf-21 polypeptides and uses thereof | |
| HK1231471A1 (en) | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2- | |
| IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| HUE044571T2 (en) | Modified cyclopentapeptides and uses thereof | |
| SG10201912019WA (en) | Novel specific-binding polypeptides and uses thereof | |
| GB201405784D0 (en) | Novel methods, polypeptides and uses thereof | |
| GB201410031D0 (en) | Polypeptides and uses thereof | |
| IL251289B (en) | Novel peptide derivatives and uses thereof | |
| SG11201610918RA (en) | Peptides and uses thereof | |
| GB201613142D0 (en) | Polypeptides and uses thereof | |
| GB201613143D0 (en) | Polypeptides and uses thereof | |
| RS62066B1 (en) | Modified fgf-21 polypeptides and uses thereof | |
| PL3229772T3 (en) | 6-aryl-9-glycosylpurines and use thereof | |
| GB201401973D0 (en) | Antibody polypeptides and uses thereof | |
| GB201407419D0 (en) | Conductive materials and uses thereof | |
| GB201403024D0 (en) | Polypeptides |